Department of General Surgery, Queen Elizabeth University Hospital, 1345 Govan Road, Glasgow, G51 4TF, United Kingdom.
Department of General Surgery, Queen Elizabeth University Hospital, 1345 Govan Road, Glasgow, G51 4TF, United Kingdom.
Eur J Surg Oncol. 2019 Apr;45(4):631-634. doi: 10.1016/j.ejso.2019.01.006. Epub 2019 Jan 4.
Adrenal metastases can arise from different primary sites. Surgical resection of the adrenal gland in patients with isolated metastases may offer improved survival in many of these patients. However, the benefit of surgery in this heterogenous group is often disputed. The aim of this study was to identify patients undergoing adrenalectomy for isolated metastases and to describe survival outcomes based on origin of the primary malignancy.
Patients undergoing surgery for isolated adrenal metastases were retrospectively analysed from a prospectively kept database. Data collected included the age of the patient, gender, size and functional status of the tumour and the site of the primary malignancy. Overall survival and survival based on the primary tumour were calculated using Kaplan-Meier survival analyses.
42 patients were included for analysis. The median tumour size was 40 mm. 91% (n = 38) of operations were performed laparoscopically. Metastases were from the following primary organs: kidney (n = 22), lung (n = 11), breast (n = 2), gastric (n = 1), skin (n = 3), liver (n = 2) and neuroendocrine (n = 1). Overall median survival was 56 (19-93) months with 95% of patients followed up for >6 months. There was a significant difference in median survival between primary organs of origin: 83(42-123), 14(9-18), 15 and 12(3-20) months (p < 0.05) for kidney, lung, breast and skin respectively.
There is a potential survival benefit for patients undergoing surgery for isolated adrenal metastases; however this survival benefit is greater in patients undergoing resection for metastases arising from kidney primaries. A selective approach should be adopted to identify patients that will clearly benefit from surgery.
肾上腺转移瘤可起源于不同的原发部位。对于孤立性转移瘤患者,手术切除肾上腺可能会改善许多患者的生存。然而,对于这种异质性患者群体,手术的获益常常存在争议。本研究旨在确定接受孤立性肾上腺转移瘤切除术的患者,并根据原发恶性肿瘤的来源描述生存结局。
回顾性分析了从前瞻性保存的数据库中接受手术治疗孤立性肾上腺转移瘤的患者。收集的数据包括患者年龄、性别、肿瘤大小和功能状态以及原发肿瘤部位。使用 Kaplan-Meier 生存分析计算总生存率和基于原发肿瘤的生存率。
共纳入 42 例患者进行分析。肿瘤的中位大小为 40mm。91%(n=38)的手术为腹腔镜下进行。转移瘤来源于以下原发器官:肾脏(n=22)、肺(n=11)、乳腺(n=2)、胃(n=1)、皮肤(n=3)、肝脏(n=2)和神经内分泌肿瘤(n=1)。总体中位生存期为 56(19-93)个月,95%的患者随访时间>6 个月。原发器官来源的中位生存期有显著差异:肾脏、肺、乳腺和皮肤的中位生存期分别为 83(42-123)、14(9-18)、15 和 12(3-20)个月(p<0.05)。
对于接受孤立性肾上腺转移瘤切除术的患者,手术可能有生存获益;然而,对于接受切除肾原发转移瘤的患者,这种生存获益更大。应采用选择性方法来识别将从手术中明显获益的患者。